Biogen
BIIB
₹11,146
Share price
-2.06%
Change (1 day)
-41.44%
Change (1 year)
Categories
Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
Biogen (BIIB) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : ₹946.80 Billion
According to Biogen's latest financial reports the company's total liabilities are ₹946.80 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Biogen - Total liabilities on balance sheet (from 2001 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | ₹972.24 B | -3.04% |
| 2023-12-31 | ₹1.002 T | 8.53% |
| 2022-12-31 | ₹923.96 B | -3.9% |
| 2021-12-31 | ₹961.47 B | -5.64% |
| 2020-12-31 | ₹1.018 T | 2.83% |
| 2019-12-31 | ₹990.88 B | 15.61% |
| 2018-12-31 | ₹857.06 B | 21.42% |
| 2017-12-31 | ₹705.83 B | -3.36% |
| 2016-12-31 | ₹730.39 B | 8.5% |
| 2015-12-31 | ₹673.18 B | 203.42% |
| 2014-12-31 | ₹221.86 B | 10.76% |
| 2013-12-31 | ₹200.32 B | 15.55% |
| 2012-12-31 | ₹173.36 B | 24.96% |
| 2011-12-31 | ₹138.73 B | 17.14% |
| 2010-12-31 | ₹118.43 B | 11.46% |
| 2009-12-31 | ₹106.25 B | -16.42% |
| 2008-12-31 | ₹127.13 B | 4.68% |
| 2007-12-31 | ₹121.44 B | 95.44% |
| 2006-12-31 | ₹62.14 B | -6.43% |
| 2005-12-31 | ₹66.41 B | -34.45% |
| 2004-12-31 | ₹101.31 B | -9.2% |
| 2003-12-31 | ₹111.57 B | 144.92% |
| 2002-12-31 | ₹45.55 B | 153.66% |
| 2001-12-31 | ₹17.95 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | ₹7.122 T | 652.28% | 🇺🇸 USA |
 Gilead Sciences GILD | ₹3.199 T | 237.93% | 🇺🇸 USA |
 AbbVie ABBV | ₹11.537 T | 1,118.55% | 🇺🇸 USA |
 Pfizer PFE | ₹10.054 T | 961.94% | 🇺🇸 USA |
 Johnson & Johnson JNJ | ₹9.897 T | 945.39% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | ₹22.89 B | -97.58% | 🇺🇸 USA |
 Sanofi SNY | ₹5.325 T | 462.49% | 🇫🇷 France |
 Bio-Rad Laboratories BIO | ₹243.88 B | -74.24% | 🇺🇸 USA |
 Illumina ILMN | ₹326.66 B | -65.50% | 🇺🇸 USA |
 Qiagen QGEN | ₹183.07 B | -80.66% | 🇳🇱 Netherlands |